Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Wasik

Showing results (241-250 of 278) with videos related to

Pageof 28
Sort By:
Frontiers in Oncology|July 24, 2019
Dynamic Changes in Gene Mutational Landscape With Preservation of Core Mutations in Mantle Cell Lymphoma CellsQian Zhang, Hong Y Wang, Xiaobin Liu, et al.
Annals of Human Genetics|February 3, 2026
Mitonuclear Discordance and Gout, Type 2 Diabetes and Chronic Kidney Disease in Aotearoa New Zealand Indigenous Māori and Pacific PeopleRachel R Dickerson, Riku Takei, Murray Cadzow, et al.
Molecular Cancer Research : MCR|June 22, 2017
IGH/MYC Translocation Associates with BRCA2 Deficiency and Synthetic Lethality to PARP1 InhibitorsSilvia Maifrede, Kayla Martin, Paulina Podszywalow-Bartnicka, et al.
Leukemia|June 13, 2014
B-lymphoid tyrosine kinase (Blk) is an oncogene and a potential target for therapy with dasatinib in cutaneous T-cell lymphoma (CTCL)D L Petersen, T Krejsgaard, J Berthelsen, et al.
Cell Cycle (Georgetown, Tex.)|May 17, 2013
STAT5-mediated expression of oncogenic miR-155 in cutaneous T-cell lymphomaKatharina L Kopp, Ulrik Ralfkiaer, Lise Mette R Gjerdrum, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 10, 2010
Immune modulators as therapeutic agents for cutaneous T-cell lymphomaAlain H Rook, Bernice Benoit, Ellen J Kim, et al.
Anticancer Research|October 3, 2014
STAT3 activation and infiltration of eosinophil granulocytes in mycosis fungoidesSimon Fredholm, Lise Mette R Gjerdrum, Andreas Willerslev-Olsen, et al.
Blood|February 12, 2016
Normal ABL1 is a tumor suppressor and therapeutic target in human and mouse leukemias expressing oncogenic ABL1 kinasesYashodhara Dasgupta, Mateusz Koptyra, Grazyna Hoser, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|March 4, 2008
EBV PCR in the diagnosis and monitoring of posttransplant lymphoproliferative disorder: results of a two-arm prospective trialD E Tsai, L Douglas, C Andreadis, et al.
Blood|June 11, 2020
Transdifferentiation of lymphoma into sarcoma associated with profound reprogramming of the epigenomeQian Zhang, Elena J Orlando, Hong Y Wang, et al.
Pageof 28

Showing results (241-250 of 278) with videos related to

Sort By:
Pageof 28
Frontiers in Oncology|July 24, 2019
Dynamic Changes in Gene Mutational Landscape With Preservation of Core Mutations in Mantle Cell Lymphoma CellsQian Zhang, Hong Y Wang, Xiaobin Liu, et al.
Annals of Human Genetics|February 3, 2026
Mitonuclear Discordance and Gout, Type 2 Diabetes and Chronic Kidney Disease in Aotearoa New Zealand Indigenous Māori and Pacific PeopleRachel R Dickerson, Riku Takei, Murray Cadzow, et al.
Molecular Cancer Research : MCR|June 22, 2017
IGH/MYC Translocation Associates with BRCA2 Deficiency and Synthetic Lethality to PARP1 InhibitorsSilvia Maifrede, Kayla Martin, Paulina Podszywalow-Bartnicka, et al.
Leukemia|June 13, 2014
B-lymphoid tyrosine kinase (Blk) is an oncogene and a potential target for therapy with dasatinib in cutaneous T-cell lymphoma (CTCL)D L Petersen, T Krejsgaard, J Berthelsen, et al.
Cell Cycle (Georgetown, Tex.)|May 17, 2013
STAT5-mediated expression of oncogenic miR-155 in cutaneous T-cell lymphomaKatharina L Kopp, Ulrik Ralfkiaer, Lise Mette R Gjerdrum, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 10, 2010
Immune modulators as therapeutic agents for cutaneous T-cell lymphomaAlain H Rook, Bernice Benoit, Ellen J Kim, et al.
Anticancer Research|October 3, 2014
STAT3 activation and infiltration of eosinophil granulocytes in mycosis fungoidesSimon Fredholm, Lise Mette R Gjerdrum, Andreas Willerslev-Olsen, et al.
Blood|February 12, 2016
Normal ABL1 is a tumor suppressor and therapeutic target in human and mouse leukemias expressing oncogenic ABL1 kinasesYashodhara Dasgupta, Mateusz Koptyra, Grazyna Hoser, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|March 4, 2008
EBV PCR in the diagnosis and monitoring of posttransplant lymphoproliferative disorder: results of a two-arm prospective trialD E Tsai, L Douglas, C Andreadis, et al.
Blood|June 11, 2020
Transdifferentiation of lymphoma into sarcoma associated with profound reprogramming of the epigenomeQian Zhang, Elena J Orlando, Hong Y Wang, et al.
Pageof 28